Recombinant Human Tumor necrosis factor receptor superfamily member 11B protein(TNFRSF11B) (Active)

In Stock
Code CSB-AP002991HU
Size US$1637Purchase it in Cusabio online store
(only available for customers from the US)
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity >95% as determined by SDS-PAGE and HPLC.
Endotoxin Less than 1.0 EU/μg as determined by LAL method.
Activity Fully biologically active when compared to standard. The ED50 as determined by neutralizing the stimulation of U937 cells is less than 10 ng/ml, corresponding to a specific activity of >1.0x105 IU/mg in the presence of 10 ng/mL soluble rHuRANKL (sRANKL).
Target Names TNFRSF11B
Uniprot No. O00300
Research Area Immunology
Alternative Names MGC29565; OCIF; OPG; Osteoclastogenesis inhibitory factor; Osteoprotegerin; PDB5; TNF receptor superfamily member 11b; TNFRSF 11B; TNFRSF11B; TR 1; TR1; TR11B_HUMAN; Tumor necrosis factor receptor superfamily member 11B
Species Homo sapiens (Human)
Source Yeast
Expression Region 22-201aa
Mol. Weight 109.6 kDa
Protein Length Partial
Tag Info C-terminal FC-tagged
Form Lyophilized powder
Buffer Lyophilized from a 0.2µm filtered 20 mM PB, pH 6.0, 150 mM NaCl, 0.02 % Tween-80
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Basically, we can dispatch the products out in 5-10 working days after receiving your orders. Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA Please contact us to get it.

Target Data

Function Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.
Gene References into Functions
  1. REVIEW: role of osteoprotegerin in the crosstalk between vessels and bone: circulating OPG levels could be used as independent biomarkers of cardiovascular disease in patients with acute or chronic cardiometabolic disease and thus an improved prognosis PMID: 28867452
  2. OPG is one promising susceptibility gene of bone mineral density or osteoporotic fractures. PMID: 28496203
  3. The concentration of circulating osteoprotegerin can be a biomarker for both medial artery calcification and atherosclerosis in patients with chronic kidney disease (CKD); OPG might be an early indicator of all-cause mortality in CKD patients with advanced medial arterial calcification PMID: 29974642
  4. We conclude that non-small cell lung cancer patients have a higher content of OPG in bronchoalveolar lavage fluid than healthy people. PMID: 29052177
  5. positive correlation of OPG with age and an inverse correlation with IGF-I favor the compensatory response of OPG against bone loss in the aging skeleton PMID: 29895074
  6. The results indicated that mice treated with low levels of human recombinant OPG may have a more stable aneurysmal phenotype due to compensatory production of collagen and increased vessel wall thickness of the aorta, potentially protecting the aneurysm from rupture. PMID: 29749489
  7. TNF-alpha, DKK1, and OPG have roles in pathogenesis of knee osteoarthritis PMID: 28676900
  8. OPG mRNA expression was higher in tumour tissue from patients with metastatic prostate cancer compared to local disease. The RANKL/OPG ratio was low in normal prostate tissue and high in tumours with bone metastases. Expression was high in BPH tissue but did not exceed as much as in the tumour tissue. PMID: 29204705
  9. results of this study concluded that the RANK, RANK-L and OPG system participates in bone remodeling after RME PMID: 29297549
  10. In cardiovascular risks, OPG serum level might increase as a preventive compensatory mechanism to neutralize the RANKL level increment. The determination of the OPG-RANKL system is a diagnostic indicator for the intensity of vascular calcification and atherosclerosis in SSc patients. PMID: 29336616
  11. Demonstrate that rs3134069 in TNFRSF11B increases risk of ischemic stroke by decreasing TNFRSF11B expression. PMID: 29501268
  12. sRANKL and OPG may play a role in the pathogenesis of diabetes as well as metabolic disturbance PMID: 28146138
  13. The study revealed an enhanced sensitivity of aortic valve interstitial cells to osteogenic inductors in aortic stenosis patients, which indicates probable implication of OPN, OPG, and BMP2 genes in pathogenesis of aortic valve calcification. PMID: 29308559
  14. Patients with metabolic syndrome have increased osteoprotegerin serum levels than healthy individuals; osteoprotegerin plays an important role in the development of arteriosclerosis, and the effect of osteoprotegerin on intima media thickness strongly depends on the extent of arteriosclerotic changes in metabolic syndrome PMID: 29077157
  15. In African-Americans, higher OPG levels were associated with characteristics common in patients with heart failure with preserved ejection fraction (HFpEF) and were significantly associated with known precursors to HFpEF. PMID: 28787318
  16. rs2073618 not associated with bone mineral density PMID: 28488893
  17. TRACP-5b level is significantly associated with the OPG level and with the severity and extent of coronary atherosclerosis in coronary artery disease patients PMID: 28428481
  18. Vascular smooth cells are a significant source of osteoprotegerin within the vasculature but that RANKL, once present, downregulates this production and appears capable of preventing the "protective" upregulation of OPG seen with VSMCs exposed to physiological levels of cyclic strain. PMID: 29635231
  19. higher serum OPG levels represent an independent risk factor for cardiovascular and fracture risk. PMID: 28677166
  20. For the OPG gene, an association was observed between the group with chronic arthralgia and joint TMD and the control group (P=0.04). There was also a tendency towards an association of the haplotype CGCCAA with an increased risk of developing chronic joint pain, even in the absence of TMD (P=0.06). PMID: 28464982
  21. Vitamin D, tumor necrosis factor (TNF)-alpha, receptor activator of nuclear factor-KB ligand (RANKL), and OPG levels were determined in GCF and serum. Baseline clinical parameters were similar in all periodontitis groups (P > 0.05) but were higher than that in controls PMID: 28904316
  22. Adipose-derived stem cell-released osteoprotegerin protects cardiomyocytes from reactive oxygen species-induced cell death. PMID: 28931423
  23. down-regulated miR-143-5p promotes the differentiation of DPSCs into odontoblasts by enhancing Runx2 expression via the OPG/RANKL signaling pathway. PMID: 28608628
  24. OPG and OPG/TRAIL ratio expression were significantly increased in rheumatoid arthritis patients compared to controls (fold change = 1.79, p = 0.013 and 2.07, p = 0.030, respectively), RANKL/OPG ratio was significantly decreased (fold change = 0.50, p = 0.020). No significant differences were found between patients and controls in RANKL and TRAIL expression. PMID: 27403809
  25. Elevated OPG was a strong and independent predictor of longterm cardiovascular mortality, even after adjustment for traditional risk factors. Low levels of both OPG and act vWF were associated with a 99 % survival rate during the follow-up of five years. PMID: 28726980
  26. This study revealed a significant elevation of circulating OPG in septic patients with different levels of severity and those who progressed to AKI. PMID: 28840836
  27. Studied association between osteoprotegerin gene polymorphisms and osteoporosis in Roma and non-Roma postmenopausal women in Eastern Slovakia. PMID: 27859736
  28. In type 2 diabetes patients HMGB-1 and OPG serum levels are higher in patients affected by peripheral arterial disease and independently associated with its occurrence and clinical severity PMID: 28789654
  29. The epicardial adipose tissue expresses the mRNA of osteopontin, osteoprotegerin, and osteonectin genes that have been implicated in the calcification process; such expression is statistically associated with some components of HDL subclasses in coronary artery disease patients. PMID: 28821297
  30. Serum osteoprotegerin level is significantly associated with both the presence and severity of peripheral arterial disease in patients with type 2 diabetes. PMID: 29313442
  31. Serum osteoprotegerin was the strongest risk factor associated with new development and rapid progression of arterial calcification in incident peritoneal dialysis patients. PMID: 28614819
  32. concluded that in Mexican-Mestizo female patients with rheumatoid arthritis, the rs2073618 polymorphism of the TNRFS11B gene is not associated with low bone mineral density PMID: 28758134
  33. Osteoprotegerin was associated with chronic kidney disease in hypertensive patients. PMID: 28683789
  34. Data suggest that, in children with type I diabetes, serum levels of osteoprotegerin are up-regulated, serum levels of RANKL are unchanged, and serum levels of fetuin-A are down-regulated. (RANKL = receptor activator of nuclear factor kappa B ligand) PMID: 27028343
  35. Data indicate a significant inverse relationship between plasma osteoprotegerin (OPG) levels and breast cancer risk among women with an inherited BRCA1 or BRCA2 mutation. PMID: 27893411
  36. Progressive calcification of atherosclerotic plaques is accompanied by insignificant accumulation of calcitonin and osteoprotegerin, whereas the osteocalcin expression significantly increased during calcification. PMID: 28429221
  37. Elevated serum ferritin concentrations and bone remodeling marker, osteoprotegerin, are independent predictors of hip fracture in postmenopausal women hospitalized for fragility fracture. PMID: 27503623
  38. Results showed that colorectal liver metastasis tissues exhibited significantly reduced expression of osteoprotegerin compared to primary colorectal carcinomas and normal colorectal mucosa. This reduced expression was significantly associated with the extent of colorectal liver metastasis, including multiplicity of metastatic tumors, involvement of the bilateral hepatic lobes, and higher histological grade. PMID: 27764814
  39. Data indicate that the RANKL/RANK/OPG system is deregulated in post-menopausal women at high risk for breast cancer and in women with circulating tumor cells. Thus, serum levels of RANKL/OPG are potentially indicative of predisposition and progression of breast cancer in humans. PMID: 28002811
  40. High OPG expression is associated with triple negative breast cancer. PMID: 27015557
  41. show for the first time that OPG improves risk stratification for cardiovascular events in a non-dialysis chronic kidney disease population PMID: 27016924
  42. OPG has a role in cancer progression, especially breast cancer [review] PMID: 27072583
  43. OPG rs2073618 polymorphism could be a possible genetic marker for the prediction of increased risk for carotid plaque burden as a measure of advanced subclinical atherosclerosis in T2DM subjects. PMID: 28593808
  44. The compound with greatest potential is E05657 with high activity and low effective concentration in the HTS system. It increases the OPG/RANKL ratio and OPG secretion, decreases the NFATc1 expression, and reduces osteoclastogenesis in vitro PMID: 27301430
  45. OPG T950C polymorphism might be associated with an increased osteoporosis risk in the Chinese population PMID: 29253005
  46. We have concluded that low OPG levels may be associated with osteoporosis in ulcerative colitis, but it is not correlated with the c.-223C > T polymorphism in the TNFRSF11B gene. PMID: 27639566
  47. RANKL/Osteoprotegerin have roles in bone turnover in Hashimoto Thyroiditis PMID: 27328677
  48. High OPG expression is associated with colorectal carcinoma. PMID: 26942563
  49. Data suggest that elevated plasma levels of osteoprotegerin/TNFRSF11B correlate with increased risk of cardiovascular comorbidities in children and adolescents with type 1 diabetes (as compared to healthy control subjects); thus, osteoprotegerin/TNFRSF11B may serve as biomarker of cardiovascular risk in these patients. This study was conducted in Tunisia. PMID: 27111559
  50. Studies showed that the central hypothalamic-pituitary regulatory system, via it's relative hormones, seems to control OPG/RANKL/RANK system function, and the pulsatility and circadian rhythmicity of these hormones may induce an oscillatory fluctuation of the OPG/ RANKL ratio. Also, psycological characteristics may provoke a shift of the OPG/ RANKL ratio towards an unbalanced or a balanced status. [review] PMID: 27862210
  51. Formulation and in vitro and in vivo evaluation of a new osteoprotegerin-chitosan gel for bone tissue regeneration PMID: 27684563
  52. The RANKL/OPG ratio significantly increased in the presence of bone metastasis with appropriate sensitivity and specificity (73% and 72%, respectively) at a cutoff of >/=0.14 for the detection of bone metastasis. Serum OPG and RANKL/OPG ratios are promising biomarkers for detecting bone metastasis in breast cancer patients. PMID: 27983911
  53. Osteoprotegerin facilitates pulmonary arterial hypertension pathogenesis by regulating pulmonary arterial smooth muscle cell proliferation via integrin alphavbeta3/FAK/AKT signaling pathway. PMID: 28077433
  54. Elevated osteoprotegerin concentration is associated with an increased risk of incident cardiovascular disease in the general population PMID: 28837646
  55. Physical activity does not increase circulating osteoprotegerin level. PMID: 28056805
  56. OPG may be a potential driver of lung cancer cells and therefore might have potential in therapy and diagnostics. PMID: 28739719
  57. our findings suggest OPG is a downstream effector of IL1B-mediated invasion in breast cancer cells. PMID: 28143606
  58. SNPs rs3102735, rs2073618 and rs3134069 of osteoprodegerin gene polymorphisms are not susceptibility factors of rheumatoid arthritis based on currently available evidence. [meta-analysis] PMID: 27156396
  59. measurement of serum osteoprotegerin concentration might be useful as a surrogate marker for determining bone loss in patients with chronic kidney disease, especially for women, although not so much for men. PMID: 27855207
  60. In patients with tightly controlled rheumatoid arthritis, serum OPG was inversely associated with progression of joint destruction. PMID: 27911913
  61. estrogen may post-transcriptionally regulate OPG expression through suppression of miR-145 expression. PMID: 28260003
  62. TNFRSF11B mutation is associated with Juvenile Paget's disease. PMID: 27809640
  63. Review: OPG, RANKL and TRAIL are involved in vascular calcification. PMID: 26924459
  64. we report the involvement of OPG in cellular and molecular changes in MVP isolated cells. In addition, we detected elevated circulating OPG levels in MVP patients when compared to controls, which supports the hypothesis that OPG is involved in MVP development and progression. PMID: 27338002
  65. Our results suggest that the polymorphism of the RANKL, RANK, and OPG genes does not make a significant genetic contribution to heel ultrasound measurements in a population of young Caucasian adults. Further studies replicating the results in independent populations are needed to support these initial findings. PMID: 28252575
  66. The study results showed that people carrying the CC genotype of rs2073618 were more likely to have peri-implantitis than GG genotype carriers (OR=2.18). Patients with the C allele had 1.47 times the risk of suffering from peri-implantitis (OR=1.47), but not rs2073617 polymorphism. The G-C haplotype frequency of rs2073618-rs2073617 in OPG was significantly correlated to the increased susceptibility of peri-implantitis. PMID: 27828936
  67. OPG rs2073618, RANK rs75404003, and RANKL rs9594782 single nucleotide poymorphisms may predispose LVH in thalassemia patients. PMID: 28244588
  68. The expression for RANKL and OPG and the RANKL/OPG ratio were not significantly different between symptomatic and asymptomatic periapical lesions. PMID: 27771584
  69. HBOT increased serum OPG levels but receptor activator of nuclear factor kappa-B ligand (RANKL) levels did not change. PMID: 28385082
  70. In conclusion, TMPRSS3 and TNFRSF11B may have potential prognostic value to be used as tumor biomarkers in breast cancer patients. PMID: 28260080
  71. High OPG expression is associated with osteoporosis. PMID: 27614458
  72. Preterm neonates exposed to Antenatal Glucocorticosteroid have higher serum levels of OPG, while premature neonates not exposed to Antenatal Glucocorticosteroid have serum OPG and RANKL levels similar to those measured in healthy term neonates. PMID: 26982319
  73. the genetic variants of the OPG gene play an intricate role in the development of alcohol-induced ONFH, and interactions among loci in the OPG gene may be more important than a single locus. This study offers important insights into the aetiology of alcohol-induced ONFH. PMID: 27994198
  74. Twenty-one single-nucleotide polymorphisms (SNPs) of TNFSF11, TNFRSF11A, and TNFRSF11B were genotyped. Two SNPs of TNFRSF11B (rs11573819 and rs2073618) were significantly associated with T2DM (p = 0.04 and p = 0.009, respectively). This study suggests that TNFRSF11B but not TNFSF11 and TNFRSF11A genetic polymorphisms are associated with Type 2 Diabetes Mellitus in Southern Han Chinese women. PMID: 27171030
  75. Findings suggest that the OPG rs3102735 gene polymorphism might be related to the occurrence of large artery atherosclerosis ischemic stroke, microembolic signals and stroke severity and not the degree of vascular stenosis. PMID: 28249772
  76. These data provide the first evidence to suggest the critical function of miR145 in regulating the expression of TNFRSF11B, which may have important implications on the regulation of chondrocyte proliferation and fibrosis in osteoarthritis. PMID: 27922673
  77. results suggest that serum OPG and RANKL levels are inversely associated with bone loss in men with advanced stage COPD. PMID: 27411457
  78. These data show that the osteoprotegerin and receptor-activator of nuclear factor-kappaB ligand system is associated with bone markers and bone mineral density at the lumbar spine after obesity surgery. PMID: 26438320
  79. Serum OPG level is associated with disease progression and death and enhance risk prediction in non-dialysis chronic kidney disease stages 3-5. PMID: 27334353
  80. OPG/TRAIL ratio can be proposed as a predictor of cardiovascular dysfunction and mortality. PMID: 27128817
  81. In ankylosing spondylitis patients, the serum OPG levels were not significantly correlated with pulse wave velocity and carotid intima-media thickness, but were significantly correlated with erthrocyte sedimentation rate, Bath Ankylosing Spondylitis Functional Index, and Ankylosing Spondylitis Disease Activity Score. PMID: 26847856
  82. The expression of Lrp6 was unaltered in the osteometastatic lesions. This negative regulation was associated with a lowered expression of osteoprotegerin in the osteometastatic lesions, an observation that was previously reported to promote osteoclastogenesis. PMID: 27310953
  83. OPG and RANKL polymorphisms were associated with the occurrence of alcohol-induced ONFH. PMID: 27336899
  84. Results demonstrated that the type of inflammatory infiltrate present in periradicular cysts appears to influence the expression of RANK, RANKL, and osteoprotegerin PMID: 25956608
  85. The aim of this meta-analysis was to determine whether genetic polymorphisms in the osteoprotegerin (OPG) gene contribute to increased risk of cardiovascular disease (CVD). The results indicated that OPG gene polymorphism might be closely associated with susceptibility to CVD, especially for rs2073617 T>C and rs2073618 G>C polymorphisms. PMID: 27068490
  86. Osteoprotegerin reduction seems to play a pivotal role in the progression of arthropathy in hemophilia A. PMID: 26494839
  87. this study shows that OPG constitutes a novel biomarker with prognostic significance in patients with severe malaria PMID: 26766771
  88. Overexpression of OPG in OCCM-30 cells promotes cementoblastic activity PMID: 27379348
  89. This study demonstrates that clodronate decreases the compression-induced RANKL/OPG ratio expressed by human osteoblasts. PMID: 26446504
  90. OPG and RANKL may play an integral role in breast cancer cells homing to the bone environment PMID: 26781475
  91. This study implicates that osteoprotegerin gene variants may be associated with early-onset severe pre-eclampsia. PMID: 25256810
  92. In lung cancer, serum OPG levels in the BM and BM- groups were significantly increased compared with healthy controls. PMID: 26671549
  93. Alendronate stimulated OPG mRNA and protein expression, but not RANKL expression, in fibroblasts from patients with aseptic loosening following total hip arthroplasty. PMID: 26351115
  94. Single nucleotide polymorphisms (SNPs) rs1035798 in RAGE gene, rs2073617 and rs2073618 in TNFRSF11B, and rs3732410 in Golgb1 will be investigated on whether there is an association with hemorrhagic stroke (HS) in Chinese population. PMID: 26664786
  95. Hypoxia can affect the expression of RANKL and OPG in human periodontal ligament cells PMID: 26722486
  96. Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-kappaB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers PMID: 26629528
  97. expression of OPG, RANK and RANKL genes exert a crucial role in the progression of avascular necrosis PMID: 26617755
  98. Studies demonstrate that OPG induces proliferation, angiogenesis, aneuploidy and survival through manipulation of various survival and aneuploidy related kinases in human mammary epithelial cells spheres. PMID: 26608463
  99. Germline variation in TNFRSF11B gene is associated with the risk of multiple myeloma bone disease. PMID: 26669972
  100. genetic variation not associated with hypertension in Chinese women PMID: 25810067

Show More

Hide All

Involvement in disease Paget disease of bone 5, juvenile-onset (PDB5)
Subcellular Location Secreted
Tissue Specificity Highly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expres
Database Links

HGNC: 11909

OMIM: 239000

KEGG: hsa:4982

STRING: 9606.ENSP00000297350

UniGene: Hs.81791

Most popular with customers


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1